Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Germline Genetic Factors Affecting Interferon Alpha Therapy in Polycythemia Vera

Roland Jäger, PhD, Elisabeth Fuchs, Edith Bogner, Jelena D. Milosevic Feenstra, PhD, Kurt Krejcy, MD, Christoph Klade, PhD, Michael Zoerer, PhD, Heinz Gisslinger, MD, Robert Kralovics, PhD

Blood (2019) 134 (Supplement_1): 1685.

https://doi.org/10.1182/blood-2019-130139

Published: 2019

Journal Articles

Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Peginvera Study Results

Blood (2018) 132 (Supplement 1): 3030.

https://doi.org/10.1182/blood-2018-99-118584

Published: 2018

Journal Articles

Switch from Every Two Weeks to Every Four Weeks Administration Schedule of AOP2014, an Innovative Pegylated Interferon Alpha, in Polycythemia Very Patients Allows Maintaining of Efficacy with Improved Toxicity Profile in Phase I/II Study

Heinz Gisslinger, MD, Veronika Buxhofer-Ausch, MD, Josef Thaler, MD, Ernst Schloegl, MD, Guenther A. Gastl, MD, Dominik Wolf, MD, Robert Kralovics, PhD, Bettina Gisslinger, MSc, Karin Strecker, MD, Alexander Egle, MD, Thomas Melchardt, MD, Sonja Burgstaller, MD, Ella Willenbacher, MD, Michael Zoerer, PhD, Pavla Kadlecova, PhD, Oleh Zagrijtschuk, MD, Christoph Klade, PhD, Richard Greil, MD

Blood (2014) 124 (21): 3177.

https://doi.org/10.1182/blood.V124.21.3177.3177

Published: 2014

Journal Articles

Efficacy and Safety Of AOP2014/P1101, a Novel, Investigational Mono-Pegylated Proline-Interferon Alpha-2b, In Patients With Polycythemia Vera (PV): Update On 51 Patients From The Ongoing Phase I/II Peginvera Study

Heinz Gisslinger, MD, Veronika Buxhofer-Ausch, MD, Josef Thaler, MD, Ernst Schloegl, MD, Guenther A. Gastl, MD, Dominik Wolf, MD, Robert Kralovics, PhD, Bettina Gisslinger, Daniel Lechner, MD, Karin Strecker, MD, Alexander Egle, Thomas Melchardt, MD, Sonja Burgstaller, MD, Ella Willenbacher, MD, Michael Zoerer, PhD, Oleh Zahriychuk, MD, MSc, Christoph Klade, PhD, Richard Greil, MD

Blood (2013) 122 (21): 4046.

https://doi.org/10.1182/blood.V122.21.4046.4046

Published: 2013

Journal Articles

AOP2014, a Novel Peg-Proline-Interferon Alpha-2b with Improved Pharmacokinetic Properties, Is Safe and Well Tolerated and Shows Promising Efficacy in Patients with Polycythemia Vera (PV)

Heinz Gisslinger, MD, PhD, Robert Kralovics, Bettina Gisslinger, Daniel Lechner, MD, Veronika Buxhofer-Ausch, MD, Karin Strecker, MD, Guenther Gastl, MD, Ella Willenbacher, MD, Richard Greil, MD, Alexander Egle, MD, Thomas Melchardt, MD, Sonja Burgstaller, MD, Ernst Schloegl, MD, Franz-Josef Tarmann, MSc, Michael Zoerer, PhD, Christoph Klade, PhD, Oleh Zahriychuk, MD, Josef Thaler, MD

Blood (2012) 120 (21): 175.

https://doi.org/10.1182/blood.V120.21.175.175

Published: 2012

Journal Articles

Safety and Efficacy Profile of rAHF-PFM for Immune Tolerance Induction as Assessed In 3 Clinical Trials (PUP ITI, PRE-PAIR, and PAIR).

Gerald Spotts, PhD, Brigitt E. Abbuehl, MD, Huong D. Luu, PharmD, Clara K. Song, PharmD, Jacqueline A. Dyck-Jones, Norma Guzman-Becerra, LieLing Wu, MyungShin Oh, Michael Zoerer, Judith Jill V. Sosa, Darby E. Stephens, Linda J. Yamamoto, MD, Bruce M. Ewenstein, MD, PhD

Blood (2010) 116 (21): 3670.

https://doi.org/10.1182/blood.V116.21.3670.3670

Published: 2010

NARROW

Germline Genetic Factors Affecting Interferon Alpha Therapy in Polycythemia Vera

Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Peginvera Study Results

Switch from Every Two Weeks to Every Four Weeks Administration Schedule of AOP2014, an Innovative Pegylated Interferon Alpha, in Polycythemia Very Patients Allows Maintaining of Efficacy with Improved Toxicity Profile in Phase I/II Study

Efficacy and Safety Of AOP2014/P1101, a Novel, Investigational Mono-Pegylated Proline-Interferon Alpha-2b, In Patients With Polycythemia Vera (PV): Update On 51 Patients From The Ongoing Phase I/II Peginvera Study

AOP2014, a Novel Peg-Proline-Interferon Alpha-2b with Improved Pharmacokinetic Properties, Is Safe and Well Tolerated and Shows Promising Efficacy in Patients with Polycythemia Vera (PV)

Safety and Efficacy Profile of rAHF-PFM for Immune Tolerance Induction as Assessed In 3 Clinical Trials (PUP ITI, PRE-PAIR, and PAIR).

Email alerts

ASH Publications

American Society of Hematology

Germline Genetic Factors Affecting Interferon Alpha Therapy in Polycythemia Vera

Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Peginvera Study Results

Switch from Every Two Weeks to Every Four Weeks Administration Schedule of AOP2014, an Innovative Pegylated Interferon Alpha, in Polycythemia Very Patients Allows Maintaining of Efficacy with Improved Toxicity Profile in Phase I/II Study

Efficacy and Safety Of AOP2014/P1101, a Novel, Investigational Mono-Pegylated Proline-Interferon Alpha-2b, In Patients With Polycythemia Vera (PV): Update On 51 Patients From The Ongoing Phase I/II Peginvera Study

AOP2014, a Novel Peg-Proline-Interferon Alpha-2b with Improved Pharmacokinetic Properties, Is Safe and Well Tolerated and Shows Promising Efficacy in Patients with Polycythemia Vera (PV)

Safety and Efficacy Profile of rAHF-PFM for Immune Tolerance Induction as Assessed In 3 Clinical Trials (PUP ITI, PRE-PAIR, and PAIR).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only